As of December 31, 2023, Ocuphire had cash and cash equivalents of approximately $50.5 million. Based on current projections, management believes the present cash on hand will be sufficient to fund operations into mid-2025.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on OCUP:
- OCUP Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Ocuphire Pharma to Present in the BIO CEO & Investor Conference
- Ocuphire Pharma Welcomes Nirav Jhaveri as New CFO
- Ocuphire Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Ocuphire Pharma appoints Jayagopal as CSDO, Jhaveri as CFO